BCAL DiagnosticsASX:BDX -3.70% Current Ratio is 3.67 as of Dec. 2025, which is 38% below its 10-year median of 5.88. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, BCAL Diagnostics ranks better than 78.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BCAL Diagnostics's current ratio for the quarter that ended in Dec. 2025 was 3.67.
BCAL Diagnostics has a current ratio of 3.67. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BCAL Diagnostics's Current Ratio or its related term are showing as below:
ASX:BDX'
s Current Ratio Range Over the Past 10 Years
Min: 2.31 Med: 5.88 Max: 180.21
Current: 3.67
During the past 4 years, BCAL Diagnostics's highest Current Ratio was 180.21. The lowest was 2.31. And the median was 5.88.
ASX:BDX's Current Ratio is ranked better than 78.5% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99
vs ASX:BDX: 3.67
BCAL Diagnostics (ASX:BDX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BCAL Diagnostics Current Ratio Related Terms
BCAL Diagnostics Current Ratio Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Current Ratio distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a Current Ratio of 3.67 as of Dec. 2025. This is 38% below median its historical median of 5.88. Over the past decade, BCAL Diagnostics' Current Ratio has ranged from 2.31 to 180.21. According to the industry distribution chart, BCAL Diagnostics ranks #46 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 21.5%.
Is BCAL Diagnostics' Current Ratio too high?
BCAL Diagnostics' current Current Ratio of 3.67 is 38% below median its 10-year median of 5.88. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 180.21. The Medical Diagnostics & Research industry median Current Ratio is 1.99. BCAL Diagnostics' value of 3.67 is 84.4% above this industry median. Based on the distribution chart, BCAL Diagnostics ranks #46 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does BCAL Diagnostics' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #46 out of 214 companies for Current Ratio. This places BCAL Diagnostics in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.99. BCAL Diagnostics' value of 3.67 is 84.4% above this benchmark. Historically, BCAL Diagnostics' own Current Ratio has ranged from 2.31 to 180.21 over the past decade. While the company's 10-year median is 5.88 vs. the industry median of 1.99, BCAL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.99, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BCAL Diagnostics's current Current Ratio of 3.67 is 84.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Current Ratio is 3.67, which is 38% below median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Current Ratio of 3.67. The current Current Ratio is 3.67, which is 38% below median its 10-year median of 5.88 and 84.4% above the Medical Diagnostics & Research industry median of 1.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Current Ratio is 3.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 